What is Xbiotech's earnings per share (EPS)?

Xbiotech (XBIT) reported diluted earnings per share of $-1.49 for fiscal year 2025. This represents a -18.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Xbiotech Financials

XBIT

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Xbiotech (XBIT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Xbiotech passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.88x

For every $1 of reported earnings, Xbiotech generates $0.88 in operating cash flow (-$39.9M OCF vs -$45.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$54.0M

YoY-32.6%

Xbiotech's EBITDA was -$54.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 32.6% from the prior year.

Net Income

-$45.5M

YoY-18.2%

Xbiotech reported -$45.5M in net income in fiscal year 2025. This represents a decrease of 18.2% from the prior year.

EPS (Diluted)

$-1.49

YoY-18.3%

Xbiotech earned $-1.49 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 18.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$40.2M

YoY-24.6%

Xbiotech generated -$40.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 24.6% from the prior year.

Cash & Debt

$125.6M

YoY-27.3%

5Y CAGR-12.0%

10Y CAGR+3.3%

Xbiotech held $125.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

30M

YoY+0.0%

5Y CAGR+0.8%

10Y CAGR-0.6%

Xbiotech had 30M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-32.5%

YoY-11.3pp

5Y CAGR-29.2pp

10Y CAGR+3.9pp

Xbiotech's ROE was -32.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 11.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$47.4M

YoY+25.5%

5Y CAGR+37.8%

10Y CAGR+4.2%

Xbiotech invested $47.4M in research and development in fiscal year 2025. This represents an increase of 25.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$289K

YoY-77.8%

5Y CAGR-40.0%

10Y CAGR-18.8%

Xbiotech invested $289K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 77.8% from the prior year.

XBIT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$0-100.0%	$4.0M-78.2%	$18.4M-58.2%	$44.0M
Cost of Revenue	N/A	N/A	$0-100.0%	$651K-88.8%	$5.8M-83.2%	$34.5M
Gross Profit	N/A	N/A	$0-100.0%	$3.4M-73.3%	$12.6M+33.1%	$9.4M
R&D Expenses	$47.4M+25.5%	$37.8M+14.9%	$32.8M+4.1%	$31.5M+11.6%	$28.3M+196.7%	$9.5M
SG&A Expenses	$8.3M+76.0%	$4.7M+1.1%	$4.7M-26.1%	$6.3M-32.8%	$9.4M-48.4%	$18.2M
Operating Income	-$55.7M-31.1%	-$42.5M-13.2%	-$37.5M-8.8%	-$34.5M-37.5%	-$25.1M-37.2%	-$18.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$235K+834.4%	-$32K-113.1%	$244K+135.5%	-$688K+91.4%	-$8.0M-400.9%	-$1.6M
Net Income	-$45.5M-18.2%	-$38.5M-56.9%	-$24.6M+25.4%	-$32.9M-88.9%	-$17.4M-55.2%	-$11.2M
EPS (Diluted)	$-1.49-18.3%	$-1.26-55.6%	$-0.81+25.0%	$-1.08-86.2%	$-0.58-61.1%	$-0.36

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$5.1M-4.8%	$5.3M-54.1%	$11.6M	N/A	$7.1M-45.1%	$13.0M+32.2%	$9.8M
SG&A Expenses	N/A	$967K-3.3%	$1.0M-48.2%	$1.9M	N/A	$777K-60.8%	$2.0M+92.8%	$1.0M
Operating Income	N/A	-$6.0M+4.6%	-$6.3M+53.2%	-$13.6M	N/A	-$7.9M+47.2%	-$15.0M-37.9%	-$10.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$102K+264.3%	$28K-3.4%	$29K	N/A	$9K+136.0%	-$25K-200.0%	$25K
Net Income	N/A	-$6.0M-242.1%	-$1.8M+83.9%	-$10.9M	N/A	-$5.0M+61.4%	-$13.0M-30.0%	-$10.0M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

XBIT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$150.1M-24.6%	$199.1M-12.1%	$226.6M-7.9%	$246.1M-10.6%	$275.2M-22.2%	$353.7M
Current Assets	$127.0M-27.3%	$174.6M-13.5%	$201.7M-8.2%	$219.8M-10.9%	$246.9M-24.2%	$325.9M
Cash & Equivalents	$125.6M-27.3%	$172.7M-13.7%	$200.0M+27.2%	$157.3M-33.6%	$237.0M-0.2%	$237.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$700K-18.6%	$860K-29.3%	$1.2M	$0-100.0%	$4.1M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.7M-42.2%	$16.8M+116.6%	$7.8M+36.3%	$5.7M-1.6%	$5.8M+13.5%	$5.1M
Current Liabilities	$7.9M-47.5%	$15.1M+147.6%	$6.1M+50.0%	$4.1M+17.8%	$3.5M-13.3%	$4.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$140.3M-23.0%	$182.3M-16.7%	$218.8M-9.0%	$240.4M-10.8%	$269.4M-22.7%	$348.6M
Retained Earnings	-$136.4M-50.1%	-$90.8M-73.7%	-$52.3M-88.5%	-$27.7M-638.7%	$5.2M-94.7%	$97.6M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$150.1M-13.0%	$172.4M-3.5%	$178.7M-1.7%	$181.9M-8.7%	$199.1M-5.1%	$209.9M-2.6%	$215.6M-5.4%	$227.9M
Current Assets	$127.0M-14.8%	$149.0M-3.8%	$154.9M-1.8%	$157.7M-9.7%	$174.6M-5.7%	$185.0M-2.9%	$190.6M-6.1%	$203.1M
Cash & Equivalents	$125.6M-14.8%	$147.4M-3.6%	$152.9M-1.9%	$155.9M-9.7%	$172.7M-5.7%	$183.1M-2.9%	$188.5M-6.2%	$201.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$450K-6.3%	$480K0.0%	$480K-31.4%	$700K-4.1%	$730K-16.1%	$870K0.0%	$870K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.7M+82.1%	$5.3M-4.9%	$5.6M-21.4%	$7.2M-57.5%	$16.8M-5.1%	$17.7M-5.9%	$18.9M+1.5%	$18.6M
Current Liabilities	$7.9M+122.4%	$3.6M-7.6%	$3.9M-28.7%	$5.4M-64.2%	$15.1M-5.5%	$16.0M-6.7%	$17.1M+1.5%	$16.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$140.3M-16.0%	$167.1M-3.5%	$173.1M-0.9%	$174.7M-4.1%	$182.3M-5.1%	$192.1M-2.3%	$196.7M-6.0%	$209.3M
Retained Earnings	-$136.4M-24.6%	-$109.5M-5.8%	-$103.5M-1.7%	-$101.7M-12.0%	-$90.8M-13.1%	-$80.3M-6.7%	-$75.3M-20.9%	-$62.3M

XBIT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$39.9M-28.9%	-$31.0M-65.4%	-$18.7M-26.3%	-$14.8M-121.3%	$69.4M+206.6%	-$65.1M
Capital Expenditures	$289K-77.8%	$1.3M+260.2%	$362K-38.1%	$585K-83.4%	$3.5M-5.4%	$3.7M
Free Cash Flow	-$40.2M-24.6%	-$32.3M-69.1%	-$19.1M-23.9%	-$15.4M-123.4%	$65.9M+195.7%	-$68.9M
Investing Cash Flow	-$289K+77.8%	-$1.3M-102.1%	$61.5M+196.3%	-$63.9M-1712.5%	-$3.5M+5.4%	-$3.7M
Financing Cash Flow	-$10.3M-198.1%	$10.4M+116211.1%	-$9K	$0+100.0%	-$67.0M+83.6%	-$409.7M
Dividends Paid	N/A	N/A	N/A	$0-100.0%	$75.0M	$0
Share Buybacks	N/A	$0-100.0%	$14K	$0	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$23.0M-438.9%	-$4.3M+28.9%	-$6.0M+10.9%	-$6.7M-2.8%	-$6.5M-11.9%	-$5.8M+48.6%	-$11.4M-58.0%	-$7.2M
Capital Expenditures	$34K-69.1%	$110K+115.7%	$51K-45.7%	$94K+11.9%	$84K-75.1%	$338K-46.1%	$627K+145.9%	$255K
Free Cash Flow	-$23.0M-426.1%	-$4.4M+27.7%	-$6.0M+11.4%	-$6.8M-2.9%	-$6.6M-7.1%	-$6.2M+48.5%	-$12.0M-61.0%	-$7.5M
Investing Cash Flow	-$34K+69.1%	-$110K-115.7%	-$51K+45.7%	-$94K-11.9%	-$84K+75.1%	-$338K+46.1%	-$627K-145.9%	-$255K
Financing Cash Flow	$0	$0	$0+100.0%	-$10.3M-3721.9%	$283K+342.2%	$64K+33.3%	$48K-99.5%	$10.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$0	$0	N/A	N/A

XBIT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	83.8%+15.4pp	68.4%+46.9pp	21.5%
Operating Margin	N/A	N/A	N/A	-860.1%-723.7pp	-136.4%-94.8pp	-41.5%
Net Margin	N/A	N/A	N/A	-820.4%-725.8pp	-94.7%-69.2pp	-25.5%
Return on Equity	-32.5%-11.3pp	-21.1%-9.9pp	-11.2%+2.5pp	-13.7%-7.2pp	-6.5%-3.2pp	-3.2%
Return on Assets	-30.3%-11.0pp	-19.4%-8.5pp	-10.8%+2.5pp	-13.4%-7.0pp	-6.3%-3.2pp	-3.2%
Current Ratio	16.01+4.5	11.56-21.5	33.07-21.0	54.07-17.4	71.49-10.3	81.80
Debt-to-Equity	0.07-0.0	0.09+0.1	0.04+0.0	0.020.0	0.020.0	0.01
FCF Margin	N/A	N/A	N/A	-384.3%-742.6pp	358.4%+514.9pp	-156.5%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-3.6%-2.6pp	-1.0%+5.2pp	-6.2%	N/A	-2.6%+4.0pp	-6.6%-1.8pp	-4.8%
Return on Assets	N/A	-3.5%-2.5pp	-1.0%+5.0pp	-6.0%	N/A	-2.4%+3.6pp	-6.0%-1.6pp	-4.4%
Current Ratio	16.01-25.8	41.78+1.6	40.16+11.0	29.15+17.6	11.56-0.0	11.57+0.4	11.13-0.9	12.03
Debt-to-Equity	0.07+0.0	0.030.0	0.030.0	0.04-0.1	0.090.0	0.090.0	0.100.0	0.09
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Inflarx IFRX

$66.0M

Ovid Therapeutics Inc OVID

$332.3M

Vaxart Inc VXRT

$103.2M

CervoMed CRVO

$38.3M

Quince QNCX

$5.5M

Frequently Asked Questions

Is Xbiotech profitable?

No, Xbiotech (XBIT) reported a net income of -$45.5M in fiscal year 2025.

What is Xbiotech's EBITDA?

Xbiotech (XBIT) had EBITDA of -$54.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Xbiotech's return on equity (ROE)?

Xbiotech (XBIT) has a return on equity of -32.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Xbiotech's free cash flow?

Xbiotech (XBIT) generated -$40.2M in free cash flow during fiscal year 2025. This represents a -24.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Xbiotech's operating cash flow?

Xbiotech (XBIT) generated -$39.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Xbiotech's total assets?

Xbiotech (XBIT) had $150.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Xbiotech's capital expenditures?

Xbiotech (XBIT) invested $289K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Xbiotech spend on research and development?

Xbiotech (XBIT) invested $47.4M in research and development during fiscal year 2025.

How many shares does Xbiotech have outstanding?

Xbiotech (XBIT) had 30M shares outstanding as of fiscal year 2025.

What is Xbiotech's current ratio?

Xbiotech (XBIT) had a current ratio of 16.01 as of fiscal year 2025, which is generally considered healthy.

What is Xbiotech's debt-to-equity ratio?

Xbiotech (XBIT) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Xbiotech's return on assets (ROA)?

Xbiotech (XBIT) had a return on assets of -30.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Xbiotech's cash runway?

Based on fiscal year 2025 data, Xbiotech (XBIT) had $125.6M in cash against an annual operating cash burn of $39.9M. This gives an estimated cash runway of approximately 38 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Xbiotech's Piotroski F-Score?

Xbiotech (XBIT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Xbiotech's earnings high quality?

Xbiotech (XBIT) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.